1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Vivanza Biosciences Limited

Vivanza Biosciences Limited

VIVANZA.BO
Vivanza Biosciences LimitedIN flagBombay Stock Exchange
1.76
INR
-0.05
- -
70.40MMarket Cap

Total Valuation

Vivanza Biosciences Limited carries a market capitalization of 70.40M, placing it among publicly traded companies globally. Its enterprise value stands at 173.32M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap70.40M
Enterprise Value173.32M

Share Statistics

Vivanza Biosciences Limited currently has 40.00M shares outstanding.

Shares Outstanding40.00M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Vivanza Biosciences Limited trades at a trailing price-to-earnings ratio of 18.27. The price-to-sales ratio is 0.06, and the price-to-book ratio stands at 1.80.

PE Ratio18.27
PS Ratio0.06
PB Ratio1.80
P/TBV Ratio2.65
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Vivanza Biosciences Limited trades at an EV/EBITDA multiple of 24.36 and an EV/FCF ratio of 85.57. The EV/Sales ratio of 0.15 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 24.36 provides insight into valuation relative to core operating earnings.

EV / Sales0.15
EV / EBITDA24.36
EV / EBIT24.36
EV / FCF85.57

Financial Position

Vivanza Biosciences Limited maintains a current ratio of 1.13, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 233.84, indicating elevated leverage, while an interest coverage ratio of 2.55 demonstrates limited ability to service its debt obligations.

Current Ratio1.13
Quick Ratio0.00
Debt / Equity233.84
Debt / EBITDA14.32
Interest Coverage2.55

Financial Efficiency

Vivanza Biosciences Limited posts a return on equity of 9.91 and a return on invested capital of 3.80.

Return on Equity (ROE)9.91
Return on Assets (ROA)2.05
Return on Invested Capital (ROIC)3.80
Return on Capital Employed (ROCE)4.45
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover39.36

Taxes

Over the trailing twelve months, Vivanza Biosciences Limited has paid 1.49M in income taxes, reflecting an effective tax rate of 27.45.

Income Tax1.49M
Effective Tax Rate27.45

Stock Price Statistics

Vivanza Biosciences Limited's stock has declined approximately -28.45528% over the past 52 weeks. The 50-day moving average sits at 1.91, while the 200-day moving average is 2.05.

Beta (5Y)N/A
52-Week Price Change-28.45528%
50-Day Moving Average1.91
200-Day Moving Average2.05
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Vivanza Biosciences Limited generated 1.16B in revenue and converted that into 3.95M in net income, yielding earnings per share of 0.10. EBITDA reached 7.12M, while operating income came in at 7.12M.

Revenue1.16B
Gross Profit14.85M
Operating Income7.12M
Pretax Income5.44M
Net Income3.95M
EBITDA7.12M
EBIT7.12M
Earnings Per Share (EPS)0.10

Balance Sheet

Vivanza Biosciences Limited holds 653,000.00 in cash and equivalents against 101.92M in total debt, resulting in a net debt position of 101.27M. Total book value stands at 40.00M, with working capital of 22.03M providing operational flexibility.

Cash & Cash Equivalents653,000.00
Total Debt101.92M
Net Debt101.27M
Equity (Book Value)40.00M
Book Value Per Share0.98
Working Capital22.03M

Margins

Vivanza Biosciences Limited operates with a gross margin of 1.28, reflecting its pricing power and cost economics. The operating margin of 0.61 and net profit margin of 0.34 provide insight into operational efficiency.

Gross Margin1.28
Operating Margin0.61
Pretax Margin0.47
Profit Margin0.34
EBITDA Margin0.61

Stock Splits

Vivanza Biosciences Limited's most recent stock split took place on March 27, 2023 with a 1:10 split ratio.

Last Split Date3/27/2023
Split Ratio1:10

Scores

Vivanza Biosciences Limited posts an Altman Z-Score of 6.16, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score6.16